BMB Reports 2024; 57(2): 116-121
Therapeutic potential of BMSC-conditioned medium in an in vitro model of renal fibrosis using the RPTEC/TERT1 cell line
Yunji Kim1,#, Dayeon Kang1,2,#, Ga-eun Choi1 , Sang Dae Kim1 , Sun-ja Yang3 , Hyosang Kim4 , Dalsan You5 , Choung Soo Kim6 & Nayoung Suh1,2,*
1Department of Medical Sciences, General Graduate School, Soonchunhyang University, Asan 31538, 2Department of Pharmaceutical Engineering, College of Medical Sciences, Soonchunhyang University, Asan 31538, 3Pharmicell Co., Ltd., Seongnam 13229, 4Division of Nephrology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, 5Department of Urology, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, 6Urology Institute, Ewha Womans University Mokdong Hospital, Seoul 07985, Korea
Correspondence to: Tel: +82-41-530-1628; Fax: +82-41-530-3085; E-mail:
#These authors contributed equally to this work.
Received: December 14, 2023; Revised: December 27, 2023; Accepted: January 15, 2024; Published online: January 31, 2024.
© Korean Society for Biochemistry and Molecular Biology. All rights reserved.

cc This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
We investigated the therapeutic potential of bone marrow-derived mesenchymal stem cell-conditioned medium (BMSC-CM) on immortalized renal proximal tubule epithelial cells (RPTEC/TERT1) in a fibrotic environment. To replicate the increased stiffness characteristic of kidneys in chronic kidney disease, we utilized polyacrylamide gel platforms. A stiff matrix was shown to increase α-smooth muscle actin (α-SMA) levels, indicating fibrogenic activation in RPTEC/TERT1 cells. Interestingly, treatment with BMSC-CM resulted in significant reductions in the levels of fibrotic markers (α-SMA and vimentin) and increases in the levels of the epithelial marker E-cadherin and aquaporin 7, particularly under stiff conditions. Furthermore, BMSC-CM modified microRNA (miRNA) expression and reduced oxidative stress levels in these cells. Our findings suggest that BMSC-CM can modulate cellular morphology, miRNA expression, and oxidative stress in RPTEC/TERT1 cells, highlighting its therapeutic potential in fibrotic kidney disease.
Keywords: Chronic kidney disease, Mesenchymal stem cell-conditioned medium, Polyacrylamide gel, Renal fibrosis, Renal proximal tubule epithelial cell

Chronic kidney disease (CKD) affects over 10% of the global population and is characterized by progressive alterations in kidney structure and function (1, 2). Renal fibrosis, a common pathological outcome of CKD, involves the accumulation of extracellular matrix (ECM), leading to disruption of renal function (3, 4). Long-term kidney fibrosis is marked by glomerulosclerosis, vascular sclerosis, and tubulointerstitial fibrosis due to imbalances in kidney repair processes, including cell proliferation, inflammation, differentiation, and ECM synthesis (5). Dysregulation of these processes leads to ECM deposition, conversion to a myofibroblast phenotype, and potentially to kidney failure, scarring, and CKD progression (6). Notably, the significant presence of senescent cells, primarily observed among renal tubular epithelial cells, has been documented in various animal models and the kidneys of patients with CKD (7). This accumulation of senescent cells in renal tissues contributes to the progression of CKD. Progression to end-stage disease necessitates renal replacement therapy. However, renal transplantation has a number of challenges, prompting focus on regeneration of injured nephrons (1).

Mesenchymal stem cells (MSCs), renowned for their multipotent differentiation, homing effect, and immunomodulatory functions, have demonstrated significant potential in tissue regeneration and organ transplantation (8, 9). Recent animal studies have highlighted that both MSCs and their conditioned medium (CM) can enhance kidney function (10), an effect attributed to their paracrine and immunomodulatory activities (11-13). In vitro models, which are more affordable and convenient than animal models, have been used to understand the molecular mechanisms of MSC action in CKD. For example, albumin-induced renal proximal tubule epithelial cells (RPTECs) co-cultured with bone marrow-derived MSCs (BM-MSCs) significantly decreased the levels of epithelial-mesenchymal transition (EMT) and fibrotic markers (14). Cisplatin-induced kidney epithelial cells treated with umbilical cord-derived MSC-conditioned medium inhibited EMT and improved renal fibrosis (11), while umbilical cord-derived MSC exosomes reduced apoptosis and oxidative stress (15). One of the critical challenges in modeling CKD in vitro has been replicating the mechanical environment of the kidney, particularly the stiffness characteristic of healthy versus CKD-affected tissues. While traditional models often utilize tissue culture polystyrene (TCP), this substrate differs significantly from the in vivo conditions, primarily in terms of stiffness, which is typically much higher in TCP than physiological levels. This discrepancy is notable as kidney stiffness is a key diagnostic marker of CKD, with the kidneys of healthy individuals exhibiting stiffness in the range of approximately 3.68-8 kPa in contrast to 5.55-33.86 kPa in patients with CKD (16-18). To address this gap, recent studies have employed mechanically tunable substrates, such as collagen (19, 20), polyacrylamide (PAA) (21), polydimethylsiloxane (22), and synthetic hydrogels (23, 24). The stiffness of these substrates more accurately mimics in vivo stiffness, thereby providing a more representative environment for studying CKD.

In this study, we used a PAA gel platform to simulate the stiffness characteristic of kidneys in patients with CKD and cultured RPTEC/TERT1, a human telomerase reverse transcriptase (hTERT)-immortalized renal epithelial cell line. We found that cells cultured on a stiffer matrix exhibited elevated levels of α-smooth muscle actin (α-SMA), indicative of activated fibrogenic cells. Notably, treatment with bone marrow-derived mesenchymal stem cell-conditioned medium (BMSC-CM) significantly reduced the expression of α-SMA and vimentin under both soft and stiff conditions, suggesting reversal of fibrotic tendencies. In contrast, the epithelial marker E-cadherin and aquaporin 7 (AQP7), a water-selective membrane channel, showed increased expression following BMSC-CM treatment, especially on stiff substrates. To elucidate the molecular mechanisms of action of BMSC-CM, we conducted miRNA profiling, and identified 43 differentially expressed microRNAs (miRNAs). Target prediction and pathway analysis highlighted critical biological pathways, including cell senescence. In addition, we observed elevated levels of reactive oxygen species (ROS) under stiff conditions, which were markedly diminished following BMSC-CM treatment. Our results demonstrated that RPTEC/TERT1 can be cultured under physiologically relevant conditions of stiffness using the PAA gel platform, providing a valuable tool to monitor the in vitro therapeutic effects of BMSC-CM.


Matrix stiffness-induced morphological and α-SMA expression changes in RPTEC/TERT1

To explore the influence of substrate stiffness on the cellular morphology and expression of EMT markers in RPTEC/TERT1 cells, we created a fibrotic environment by developing PAA gels with two distinct levels of stiffness: a softer matrix at 3.9 kPa and a stiffer matrix at 32.7 kPa (Fig. 1A). The RPTEC/TERT1 cell line was then cultured on these substrates (Fig. 1B). While cell viability remained consistent between both substrates, cells cultured on the stiffer matrix exhibited increased proliferation (Supplementary Fig. 1). On the first day, cells on the softer substrate were smaller in size and had a larger aspect ratio compared with those on the stiffer substrate (Fig. 1C, D). However, after 5 days of culture, despite a similar cell area on both substrates (Fig. 1C), RPTEC/TERT1 on the stiff substrate developed significantly longer protrusions (Fig. 1D). Our analysis further extended to evaluating the expression of EMT markers. Upon transferring RPTEC/TERT1 from PAA gels to Transwell membrane filters for polarization, as described previously (25, 26), we noted a substantial increase in the level of α-SMA, a marker associated with mesenchymal cells, particularly in cells cultured on stiff substrates. This was in contrast to the expression of the epithelial-associated marker E-cadherin and another mesenchymal-associated marker, vimentin, which showed similar expression levels on both the soft and stiff matrices (Fig. 1E). Taken together, our findings suggest that RPTEC/TERT1 undergo morphological changes and express an elevated level of α-SMA when cultured on a stiff substrate.

BMSC-CM attenuates fibrosis and upregulates epithelial markers in RPTEC/TERT1

Further investigations were performed to assess the potential therapeutic effects of BMSC-CM. The CM generated from human BMSCs cultured in human platelet lysate was applied to RPTEC/TERT1 cultured under varying substrate stiffness conditions. After treatment with BMSC-CM for 24 h, we observed a notable increase in the cell area under both substrate conditions (Fig. 2A, B). The enhanced cellular protrusions were particularly evident in cells cultured on the soft substrate (Fig. 2C). Moreover, we observed significant decreases in the protein levels of mesenchymal markers, including α-SMA and vimentin, following BMSC-CM treatment, while the level of E-cadherin was increased (Fig. 2D, E). In addition, the AQP7 level, following the addition of water in the Transwell system, showed a substantial increase with BMSC-CM treatment, especially under stiff matrix conditions (Fig. 2D, E). These findings suggested that BMSC-CM not only modulates the morphological characteristics of RPTEC/TERT1 but also influences the expression of key markers, highlighting its potential therapeutic role.

Impact of BMSC-CM on miRNA expression profiles and associated pathways in RPTEC/TERT1

To understand the molecular mechanisms underpinning the effects of BMSC-CM on RPTEC/TERT1, particularly under stiff conditions, we conducted comprehensive global miRNA profiling using the NanoString nCounter human v3 miRNA expression panel. This analysis identified 43 differentially expressed miRNAs (25 upregulated and 18 downregulated) in RPTEC/TERT1 treated with BMSC-CM compared with untreated controls (P < 0.05) (Fig. 3A, B).

To understand the potential mechanisms underlying regulation of the miRNAs differentially expressed in BMSC-CM-treated RPTEC/TERT1, we attempted to determine their mRNA targets. A total of 6,126 targets of the 43 miRNAs were extracted from the miRNA target filter with high confidence levels using Ingenuity Pathway Analysis (IPA) software. We then analyzed the cellular functions and networks (Fig. 3C). The top 10 canonical pathways enriched among the target genes were associated with various biological processes and signaling pathways, including cell senescence, hepatic fibrosis signaling, regulation of the EMT by growth factor pathways, and wound healing signaling pathway (Fig. 3D). Taken together, distinct subsets of miRNAs exhibited differential expression in response to BMSC-CM treatment. Moreover, the putative target mRNAs of these miRNAs showed significant enrichment in diverse biological processes, notably cellular senescence.

Reduced oxidative stress in RPTEC/TERT1 by BMSC-CM treatment

ROS production and oxidative stress are critical contributors to cellular senescence, a state of permanent cell cycle arrest. Given the identification of senescence pathways as the top canonical pathways influenced by BMSC-CM treatment, we used the oxidation-sensitive fluorescent probe 2’7’-dichlorofluorescin diacetate (H2DCF-DA) to assess intracellular ROS levels. This analysis demonstrated significant decreases in ROS production upon BMSC-CM treatment in RPTEC/TERT1 cultured under both soft and stiff conditions (Fig. 4A). Furthermore, we confirmed decreased mitochondrial superoxide anion levels by MitoSOX staining, with significantly decreased levels of MitoSOX observed in the BMSC-CM-treated groups, including those cultured under both soft and stiff PAA gel conditions (Fig. 4B). In addition, we monitored the phosphorylation status of p53 at serine 15, a key factor in cellular senescence pathways. Consistent with the decreased levels of ROS following BMSC-CM treatment, we noted a significant decrease in phosphorylated (p)-p53-positive cells after 24 h of exposure to BMSC-CM in RPTEC/TERT1 cultured on both soft and stiff PAA gels (Fig. 4C). Quantitative analysis revealed that the p-p53 level was reduced by 32.2% and 34.5% under soft and stiff conditions, respectively (Fig. 4D). Taken together, these findings suggested that BMSC-CM has a multifaceted effect on RPTEC/TERT1 cultured on PAA gel, particularly by regulating oxidative stress levels, thereby reinforcing its therapeutic potential under fibrotic conditions.


Our research utilizing the PAA gel platform and cultured RPTEC/TERT1 has contributed to understanding the mechanisms of renal fibrosis and the therapeutic potential of MSCs. We demonstrated that BMSC-CM significantly reduced fibrotic marker levels in these cells, suggesting reversal of the fibrotic process, consistent with previous research underscoring the potential of MSCs in treating fibrosis (13).

Renal fibrosis, leading to end-stage kidney disease, is typically marked by excessive ECM deposition and loss of renal function. Traditional treatments have focused on inhibiting ECM production or enhancing its degradation. However, recent research identified kidney fibroblast activation and tubular epithelial cell injury as central factors involved in fibrosis (27-29). In this context, the RPTEC/TERT1 cell line serves as a critical model for understanding the fibrotic process and evaluating the therapeutic efficacy of MSC-CM.

The use of PAA gel platforms in the present study allowed us to emulate the mechanical environment of CKD in vivo. PAA gels offer biocompatibility and transparency, and their tunable stiffness enabled us to replicate the mechanical properties of renal tissue in CKD (24). This approach is crucial for understanding the often-overlooked biomechanical aspects of fibrosis in conventional in vitro models.

In the present study, we identified 43 miRNAs with differential expression in RPTEC/TERT1 treated with BMSC-CM under fibrotic conditions. This is significant as miRNAs play crucial roles in regulating gene expression and cellular processes involved in kidney diseases, including renal fibrosis (30-32). Notably, miR-21 acts as a profibrotic factor, and its upregulation is correlated with increased severity of kidney fibrosis and renal function decline, particularly in diabetic nephropathy (33, 34). Conversely, miR-27b-3p shows antifibrotic properties, effectively suppressing TGF-β1-induced EMT and reducing fibrotic marker levels, thereby attenuating renal fibrosis in vitro and in unilateral ureteral obstruction mouse models (30, 35). Intriguingly, our miRNA profiling analysis further revealed that BMSC-CM treatment led to upregulation of miR-27a-3p and miR-205, consistent with previous findings indicating that miR-205 and the miR-200 family are significantly downregulated during EMT (36). Given the regulatory role of miRNAs in fibrosis, the ability of BMSC-CM to alter miRNA expression suggests that it may have therapeutic potential. In addition, our study underscored the need for further research to elucidate the precise mechanisms by which BMSC-CM influences miRNA expression and its subsequent impact on renal fibrosis. Such investigations could involve in-depth functional analyses of the identified miRNAs, their target genes, and the associated cellular pathways. This will not only enhance our understanding of the pathophysiology of renal fibrosis but also aid in the development of miRNA-based therapeutic strategies for CKD.

In conclusion, this study highlighted the promising role of MSCs in regenerative medicine, particularly in the treatment of fibrotic diseases. BMSC-CM exhibited significant antifibrotic effects on renal cells, not only reversing changes in fibrotic markers in RPTEC/TERT1 but also altering the oxidative microenvironment. These findings elucidated the cellular and molecular mechanisms underlying renal fibrosis and support the use of MSC-based therapies in CKD and other fibrotic conditions. The insights gained from this study contribute substantially to the field, paving the way for future research in MSC-based therapeutic development for CKD and related diseases, thereby marking significant advances in the understanding and treatment of renal fibrosis.


Materials and methods are available in the Supplemental information.


This work was supported by the 2022 Sabbatical Year of Soonchunhyang University, the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2021R1I1A3048341), and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI18C0283).


The authors have no conflicting interests.

Fig. 1. The impact of matrix rigidity on RPTEC/TERT1 cellular morphology and EMT marker expression. (A) Young’s moduli (kPa) of soft and stiff PAA gels. The lines represent the median values of five independent experiments. (B) Morphology of RPTEC/TERT1 on days 1 and 5 of culture under different stiffness conditions. Scale bars, 100 μm. (C) Cell area and (D) cell aspect ratio of RPTEC/TERT1 on days 1 and 5. Central box, first to third quartile; middle line, median (n = 45 cells per group, three independent experiments, #P < 0.0001, Student’s two-tailed t test). (E) Representative immunofluorescence images of mesenchymal markers (α-SMA and vimentin) and an epithelial marker (E-cadherin) of RPTEC/TERT1 cultured on PAA gel plates. Scale bars, 25 μm.
Fig. 2. Inhibitory effects of BMSC-CM on fibrosis and promotion of epithelial marker and aquaporin 7 (AQP7) expression in RPTEC/TERT1. (A) Morphology of BMSC-CM-treated RPTEC/TERT1 cultured under different stiffness conditions. Scale bars, 100 μm. (B) Cell area and (C) cell aspect ratio of RPTEC/TERT1 in BMSC-CM-treated and untreated groups. Central box, first to third quartile; middle line, median (n = 45 cells per group, three independent experiments, **P < 0.01, #P < 0.0001, Student’s two-tailed t test). (D) Representative immunofluorescence images for mesenchymal markers (α-SMA and vimentin), an epithelial marker (E-cadherin), and a tubular marker (AQP7) in RPTEC/TERT1. Scale bars, 25 μm. (E) Quantitative measurement of the fluorescence intensities of α-SMA (soft, n = 23; stiff, n = 48; soft + CM, n = 32; stiff + CM, n = 31, three independent experiments, **P < 0.01, #P < 0.0001, Student’s two-tailed t test), vimentin (n = 48 cells per group, two independent experiments, #P < 0.0001, Student’s two-tailed t test), E-cadherin (soft, n = 43; stiff, n = 35; soft + CM, n = 28; stiff + CM, n = 43, three independent experiments, #P < 0.0001, Student’s two-tailed t test), and AQP7 (soft, n = 48; stiff, n = 48; soft + CM, n = 47; stiff + CM, n = 47, two independent experiments, **P < 0.01, #P < 0.0001, Student’s two-tailed t test) staining.
Fig. 3. Modulation by BMSC-CM of the miRNA profiles and associated pathways in RPTEC/TERT1. (A) Volcano plot of the differentially expressed miRNAs obtained from miRNA expression profiling in the stiff and stiff + CM groups. (B) Heatmap of 43 miRNAs differentially expressed between the stiff + CM and stiff samples. (C) Schematics of target prediction and pathway analysis of the differentially expressed miRNAs. (D) Predicted targets of the miRNAs were analyzed using IPA software, and the top 10 canonical pathways are shown.
Fig. 4. Decreased oxidative stress in RPTEC/TERT1 following treatment with BMSC-CM. Representative fluorescence images of RPTEC/TERT1 stained with (A) H2DCF-DA and (B) MitoSOX. Scale bars, 100 μm. (C) Representative fluorescence images of p-p53 (green), p53 (red), and F-actin (pink). Scale bars, 50 μm. (D) Quantification of p-p53 intensity in RPTEC/TERT1 (soft, n = 26; stiff, n = 26; soft + CM, n = 30; stiff + CM, n = 27, two independent experiments, #P < 0.0001, Student’s two-tailed t test).
  1. Romagnani P, Remuzzi G and Glassock R et al (2017) Chronic kidney disease. Nat Rev Dis Primers 3, 17088.
    Pubmed CrossRef
  2. Ju SH and Yi HS (2023) Clinical features and molecular mechanism of muscle wasting in end stage renal disease. BMB Rep 56, 426-438.
    Pubmed KoreaMed CrossRef
  3. Kim KP, Williams CE and Lemmon CA (2022) Cell-matrix interactions in renal fibrosis. Kidney Dial 2, 607-624.
    Pubmed KoreaMed CrossRef
  4. Wang C, Li SW, Zhong X, Liu BC and Lv LL (2023) An update on renal fibrosis: from mechanisms to therapeutic strategies with a focus on extracellular vesicles. Kidney Res Clin Pract 42, 174-187.
    Pubmed KoreaMed CrossRef
  5. Nogueira A, Pires MJ and Oliveira PA (2017) Pathophysiological mechanisms of renal fibrosis: a review of animal models and therapeutic strategies. In Vivo 31, 1-22.
    Pubmed KoreaMed CrossRef
  6. Schnaper HW (2017) The tubulointerstitial pathophysiology of progressive kidney disease. Adv Chronic Kidney Dis 24, 107-116.
    Pubmed KoreaMed CrossRef
  7. Zhang JQ, Li YY and Zhang XY et al (2023) Cellular senescence of renal tubular epithelial cells in renal fibrosis. Front Endocrinol 14, 1085605.
    Pubmed KoreaMed CrossRef
  8. Huang Y, Wu Q and Tam PKH (2022) Immunomodulatory mechanisms of mesenchymal stem cells and their potential clinical applications. Int J Mol Sci 23, 10023.
    Pubmed KoreaMed CrossRef
  9. Wang Y, Chen X, Cao W and Shi Y (2014) Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol 15, 1009-1016.
    Pubmed CrossRef
  10. Zhuang Q, Ma RY, Yin YS, Lan TH, Yu M and Ming YZ (2019) Mesenchymal stem cells in renal fibrosis: the flame of cytotherapy. Stem Cells International 2019, 8387350.
    Pubmed KoreaMed CrossRef
  11. Liu B, Ding F and Hu D et al (2018) Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF-kappaB signaling pathway in vivo and in vitro. Stem Cell Res Ther 9, 7.
    Pubmed KoreaMed CrossRef
  12. Semedo P, Correa-Costa M and Antonio Cenedeze M et al (2009) Mesenchymal stem cells attenuate renal fibrosis through immune modulation and remodeling properties in a rat remnant kidney model. Stem Cells 27, 3063-3073.
    Pubmed CrossRef
  13. Qin L, Liu N and Bao CLM et al (2023) Mesenchymal stem cells in fibrotic diseases-the two sides of the same coin. Acta Pharmacol Sin 44, 268-287.
    Pubmed KoreaMed CrossRef
  14. Wu HJ, Yiu WH and Li RX et al (2014) Mesenchymal stem cells modulate albumin-induced renal tubular inflammation and fibrosis. PLoS One 9, e90883.
    Pubmed KoreaMed CrossRef
  15. Zhou Y, Xu H and Xu W et al (2013) Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther 4, 34.
    Pubmed KoreaMed CrossRef
  16. Zhang J, Duan CR, Duan XX, Hu Y, Liu JQ and Chen WJ (2022) Quantitative evaluation of real-time shear-wave elastography under deep learning in children with chronic kidney disease. Sci Program 2022, 6051695.
  17. Guimaraes CF, Gasperini L, Marques AP and Reis RL (2020) The stiffness of living tissues and its implications for tissue engineering. Nat Rev Mater 5, 351-370.
  18. Samir AE, Allegretti AS and Zhu QL et al (2015) Shear wave elastography in chronic kidney disease: a pilot experience in native kidneys. BMC Nephrology 16, 119.
    Pubmed KoreaMed CrossRef
  19. Ishihara S, Kurosawa H and Haga H (2023) Stiffness-modulation of collagen gels by genipin-crosslinking for cell culture. Gels 9, 148.
    Pubmed KoreaMed CrossRef
  20. Ishihara S, Yasuda M, Harada I, Mizutani T, Kawabata K and Haga H (2013) Substrate stiffness regulates temporary NF-κB activation via actomyosin contractions. Exp Cell Res 319, 2916-2927.
    Pubmed CrossRef
  21. Desai SS, Tung JC and Zhou VX et al (2016) Physiological ranges of matrix rigidity modulate primary mouse hepatocyte function in part through hepatocyte nuclear factor 4 alpha. Hepatology 64, 261-275.
    Pubmed KoreaMed CrossRef
  22. Goffin JM, Pittet P, Csucs G, Lussi JW, Meister JJ and Hinz B (2006) Focal adhesion size controls tension-dependent recruitment of α-smooth muscle actin to stress fibers. J Cell Biol 172, 259-268.
    Pubmed KoreaMed CrossRef
  23. Sacchi M, Bansal R and Rouwkema J (2020) Bioengineered 3D models to recapitulate tissue fibrosis. Trends Biotechnol 38, 623-636.
    Pubmed CrossRef
  24. Davidson MD, Burdick JA and Wells RG (2020) Engineered biomaterial platforms to study fibrosis. Adv Healthc Mater 9, 1901682.
    Pubmed KoreaMed CrossRef
  25. Secker PF, Schlichenmaier N, Beilmann M, Deschl U and Dietrich DR (2019) Functional transepithelial transport measurements to detect nephrotoxicity in vitro using the RPTEC/TERT1 cell line. Arch Toxicol 93, 1965-1978.
    Pubmed CrossRef
  26. Wang XJ, Wilkinson R and Kildey K et al (2021) Molecular and functional profiling of apical versus basolateral small extracellular vesicles derived from primary human proximal tubular epithelial cells under inflammatory conditions. J Extracell Vesicles 10, e12064.
    Pubmed KoreaMed CrossRef
  27. Kim DA, Lee MR, Oh HJ, Kim M and Kong KH (2023) Effects of long-term tubular HIF-2alpha overexpression on progressive renal fibrosis in a chronic kidney disease model. BMB Rep 56, 196-201.
    Pubmed KoreaMed CrossRef
  28. Fintha A, Gasparics A, Rosivall L and Sebe A (2019) Therapeutic targeting of fibrotic epithelial-mesenchymal transition-an outstanding challenge. Front Pharmacol 10, 388.
    Pubmed KoreaMed CrossRef
  29. Yan H, Xu JX, Xu ZF, Yang B, Luo PH and He QJ (2021) Defining therapeutic targets for renal fibrosis: exploiting the biology of pathogenesis. Biomed Pharmacother 143, 112115.
    Pubmed CrossRef
  30. Gluba-Sagr A, Franczyk B, Rysz-Górzynska M, Lawinski J and Rysz J (2023) The role of miRNA in renal fibrosis leading to chronic kidney disease. Biomedicines 11, 2358.
    Pubmed KoreaMed CrossRef
  31. Ichii O and Horino T (2018) MicroRNAs associated with the development of kidney diseases in humans and animals. J Toxicol Pathol 31, 23-34.
    Pubmed KoreaMed CrossRef
  32. Zhao H, Ma SX, Shang YQ, Zhang HQ and Su W (2019) microRNAs in chronic kidney disease. Clinica Chimica Acta 491, 59-65.
    Pubmed CrossRef
  33. Glowacki F, Savary G and Gnemmi V et al (2013) Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS One 8, e58014.
    Pubmed KoreaMed CrossRef
  34. McClelland AD, Herman-Edelstein M and Komers R et al (2015) miR-21 promotes renal fibrosis in diabetic nephropathy by targeting PTEN and SMAD7. Clin Sci (Lond) 129, 1237-1249.
    Pubmed CrossRef
  35. Bai L, Lin Y, Xie J, Zhang Y, Wang H and Zheng D (2021) MiR-27b-3p inhibits the progression of renal fibrosis via suppressing STAT1. Hum Cell 34, 383-393.
    Pubmed KoreaMed CrossRef
  36. Gregory PA, Bert AG and Paterson EL et al (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10, 593-601.
    Pubmed CrossRef

This Article

Cited By Articles
  • CrossRef (0)

Author ORCID Information

Funding Information


Social Network Service